Karen Oldfield1,2, John Ryan3, Marjan Doppen1, Stacey Kung1, Irene Braithwaite1, Giles Newton-Howes4. 1. Medical Research Institute of New Zealand, Wellington, New Zealand. 2. Victoria University, Wellington, New Zealand. 3. Capital and Coast District Health Board (CCDHB), Wellington, New Zealand. 4. Department of Psychological Medicine, University of Otago (Wellington), New Zealand.
Abstract
OBJECTIVES: To review the literature regarding label accuracy and contamination of medical cannabinoid-based products. METHODS: A systematic review with meta-analysis following PRISMA guidelines. This study is registered with PROSPERO (CRD42019131565). RESULTS: Five studies reported label accuracy data ranging between 17% and 86%. Four studies reported contaminants, including pesticides, solvents and AB-FUBINACA. Meta-analysis was limited to the proportion of pesticide-contaminated samples found in two studies (0.25 (95% CI [0.10, 0.40])) and displayed significant heterogeneity. CONCLUSIONS: Label inaccuracies and contaminants are found across a spectrum of cannabinoid-based products. The review highlights the paucity and heterogeneity of research relating to cannabinoid-based products in light of changing global legislation. Further robust research is required to support ongoing pharmacovigilance and patient safety.
OBJECTIVES: To review the literature regarding label accuracy and contamination of medical cannabinoid-based products. METHODS: A systematic review with meta-analysis following PRISMA guidelines. This study is registered with PROSPERO (CRD42019131565). RESULTS: Five studies reported label accuracy data ranging between 17% and 86%. Four studies reported contaminants, including pesticides, solvents and AB-FUBINACA. Meta-analysis was limited to the proportion of pesticide-contaminated samples found in two studies (0.25 (95% CI [0.10, 0.40])) and displayed significant heterogeneity. CONCLUSIONS: Label inaccuracies and contaminants are found across a spectrum of cannabinoid-based products. The review highlights the paucity and heterogeneity of research relating to cannabinoid-based products in light of changing global legislation. Further robust research is required to support ongoing pharmacovigilance and patient safety.
Authors: Amber Salter; Robert J Fox; Gary Cutter; Ruth Ann Marrie; Kate E Nichol; Joshua R Steinerman; Karry M J Smith Journal: Int J MS Care Date: 2021-12-29
Authors: Amber Salter; Gary Cutter; Ruth Ann Marrie; Kathryn Nichol; Joshua R Steinerman; Karry M J Smith; Robert J Fox Journal: Neurol Clin Pract Date: 2022-04